Aktienanalyse zu Nurix Therapeutics Inc (NRIX)NRIXNurix Therapeutics Inc

Nurix Therapeutics, Inc. is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation medicines, aimed at improving treatment options for patients with cancer and autoimmune diseases. The Company's wholly owned, clinical stage pipeline includes degraders of Bruton’s tyrosine kinase (BTK), a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B (CBL-B), an E3 ligase that regulates activation of multiple immune cell types including T cells and NK cells. The Company's portfolio of targeted protein degraders of the B‑cell signaling protein BTK comprises bexobrutideg (NX‑5948) and zelebrudomide (NX‑2127). The Company's degradation inhibitor program includes NX-1607, an orally bioavailable inhibitor of CBL-B, an E3 ligase that regulates the activation of multiple immune cell types including T cells and NK cells. NX-1607 is targeted for immuno-oncology indications. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Nurix Therapeutics Inc is a good buy right now due to its recent collaboration with Roche, which has significantly boosted its financial position, as evidenced by a reported EPS of 4.73 and a net income of 549,807,000 USD in Q3 2026. Additionally, the current price of 24.42 is well below the average analyst price target of 33.75, indicating substantial upside potential. However, investors should be cautious of the recent volatility, with a 5-day change of +9.26% followed by a -2.12% drop yesterday, which reflects market uncertainty.